Rhythm Pharmaceuticals, Inc. carried $100.9M in long-term debt against $54.3M in cash and equivalents at the end of fiscal year 2025. Long-term debt fell 6.8% from the prior fiscal year. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Rhythm Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RYTM Debt & Cash by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY21Filing | FY2010-K | FY1910-K | FY1810-K | FY17Filing | FY16Filing | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $100.9M-6.8% | $108.3M+2.0% | $106.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $54.3M-39.1% | $89.1M+48.4% | $60.1M-52.9% | $127.7M+115.5% | $59.2M-41.3% | $100.9M+61.9% | $62.3M+25.7% | $49.5M+44.7% | $34.2M+423.5% | $6.5M-81.2% | $34.9M |
RYTM Debt & Cash by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $87.9M-15.0% | $93.4M-11.9% | $98.3M-8.9% | $100.9M-6.8% | $103.4M | $106.0M | $107.9M | $108.3M+2.0% | N/A | N/A | N/A | $106.1M |
| Cash & Equivalents | $40.0M-23.2% | $65.6M-51.6% | $62.1M-41.4% | $54.3M-39.1% | $52.1M+9.6% | $135.6M-16.1% | $106.1M+98.6% | $89.1M+48.4% | $47.5M-26.4% | $161.7M+39.8% | $53.4M-51.3% | $60.1M-52.9% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Rhythm Pharmaceuticals, Inc. financials
Frequently Asked Questions
Rhythm Pharmaceuticals, Inc. carried $100.9M in long-term debt against $54.3M in cash and equivalents at the end of fiscal year 2025.
Rhythm Pharmaceuticals, Inc. (RYTM) long-term debt fell by 6.8% year over year, from $108.3M to $100.9M in fiscal year 2025.
Rhythm Pharmaceuticals, Inc. (RYTM) reported $87.9M in long-term debt in Q3 2026. This represents a decrease of 15.0% from the same quarter a year earlier.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Rhythm Pharmaceuticals, Inc. (RYTM) reported on that line in every period on record.